136 related articles for article (PubMed ID: 11708189)
1. Didanosine (Videx).
Res Initiat Treat Action; 2000 Mar; 6(1):8-9. PubMed ID: 11708189
[No Abstract] [Full Text] [Related]
2. Zidovudine (Retrovir).
Res Initiat Treat Action; 2000 Mar; 6(1):6-7. PubMed ID: 11708188
[No Abstract] [Full Text] [Related]
3. Delavirdine (Rescriptor).
Res Initiat Treat Action; 2000 Mar; 6(1):20-1. PubMed ID: 11708180
[No Abstract] [Full Text] [Related]
4. Nevirapine (Viramune).
Res Initiat Treat Action; 2000 Mar; 6(1):18-9. PubMed ID: 11708179
[No Abstract] [Full Text] [Related]
5. Lamivudine (Epivir).
Res Initiat Treat Action; 2000 Mar; 6(1):14-5. PubMed ID: 11708177
[No Abstract] [Full Text] [Related]
6. Stavudine (Zerit).
Res Initiat Treat Action; 2000 Mar; 6(1):12-3. PubMed ID: 11708176
[No Abstract] [Full Text] [Related]
7. Zalcitabine (Hivid).
Res Initiat Treat Action; 2000 Mar; 6(1):10-1. PubMed ID: 11708175
[No Abstract] [Full Text] [Related]
8. Abacavir (Ziagen).
Res Initiat Treat Action; 2000 Mar; 6(1):16-7. PubMed ID: 11708178
[No Abstract] [Full Text] [Related]
9. Efavirenz (Sustiva).
Res Initiat Treat Action; 2000 Mar; 6(1):22-3. PubMed ID: 11708181
[No Abstract] [Full Text] [Related]
10. d4T plus ddI: warning for pregnant women.
AIDS Treat News; 2001 Jan; (358):8. PubMed ID: 12173560
[TBL] [Abstract][Full Text] [Related]
11. French investigators warn of LPV/TDF/ddI interaction.
Carter M
IAPAC Mon; 2003 Dec; 9(12):315. PubMed ID: 15055164
[No Abstract] [Full Text] [Related]
12. [Confirmed NRTI remains an important therapy option. Didanosine effective despite multiple resistance to NRTIs].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():21. PubMed ID: 15373039
[No Abstract] [Full Text] [Related]
13. New formulation of ddI approved in Canada--Videx EC.
TreatmentUpdate; 2001 Oct; 13(6):2. PubMed ID: 11768866
[No Abstract] [Full Text] [Related]
14. New questions about an old combination--ddI + d4T.
Proj Inf Perspect; 2003 Jan; (35):13-4. PubMed ID: 12647675
[TBL] [Abstract][Full Text] [Related]
15. [Anti-retroviral treatment. Treatment modification: toxicity management].
Ocaña I; Laguna F; Pulido F; Bascuñana A
Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():31-5. PubMed ID: 9053025
[No Abstract] [Full Text] [Related]
16. Pediatric efficacy supplement for Videx EC.
AIDS Patient Care STDS; 2008 Nov; 22(11):919. PubMed ID: 19043843
[No Abstract] [Full Text] [Related]
17. [Resistance to nucleoside reverse transcriptase inhibitors].
Leal M; Santamaría JM
Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):26-9. PubMed ID: 11428055
[No Abstract] [Full Text] [Related]
18. Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid.
Sax PE
AIDS Clin Care; 2005 Jan; 17(1):6-7. PubMed ID: 15717372
[No Abstract] [Full Text] [Related]
19. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
Reliquet V; Ferré V; Hascoet C; Besnier JM; Bellein V; Arvieux C; Molina JM; Breux JP; Zucman D; Rozenbaum W; Allavena C; Raffi F;
Antivir Ther; 1999; 4 Suppl 3():83-4. PubMed ID: 16021876
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir drug interactions: ddI and d4T.
TreatmentUpdate; 2003; 15(2):7. PubMed ID: 12693363
[No Abstract] [Full Text] [Related]
[Next] [New Search]
